Details for New Drug Application (NDA): 211640
✉ Email this page to a colleague
The generic ingredient in EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE is emtricitabine; tenofovir disoproxil fumarate. There are eighteen drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the emtricitabine; tenofovir disoproxil fumarate profile page.
Summary for 211640
| Tradename: | EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE |
| Applicant: | Aurobindo Pharma Ltd |
| Ingredient: | emtricitabine; tenofovir disoproxil fumarate |
| Patents: | 0 |
Pharmacology for NDA: 211640
| Mechanism of Action | Nucleoside Reverse Transcriptase Inhibitors |
Suppliers and Packaging for NDA: 211640
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE | emtricitabine; tenofovir disoproxil fumarate | TABLET;ORAL | 211640 | ANDA | Aurobindo Pharma Limited | 59651-165 | 59651-165-30 | 30 TABLET, FILM COATED in 1 BOTTLE (59651-165-30) |
| EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE | emtricitabine; tenofovir disoproxil fumarate | TABLET;ORAL | 211640 | ANDA | Aurobindo Pharma Limited | 59651-166 | 59651-166-30 | 30 TABLET, FILM COATED in 1 BOTTLE (59651-166-30) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 100MG;150MG | ||||
| Approval Date: | Mar 9, 2023 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 133MG;200MG | ||||
| Approval Date: | Mar 9, 2023 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 167MG;250MG | ||||
| Approval Date: | Mar 9, 2023 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
